CN112656766A - Fecal fungus freeze-drying and capsule preparation process for fecal fungus transplantation treatment - Google Patents
Fecal fungus freeze-drying and capsule preparation process for fecal fungus transplantation treatment Download PDFInfo
- Publication number
- CN112656766A CN112656766A CN202110070100.1A CN202110070100A CN112656766A CN 112656766 A CN112656766 A CN 112656766A CN 202110070100 A CN202110070100 A CN 202110070100A CN 112656766 A CN112656766 A CN 112656766A
- Authority
- CN
- China
- Prior art keywords
- freeze
- drying
- capsule
- fecal
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004108 freeze drying Methods 0.000 title claims abstract description 64
- 230000002550 fecal effect Effects 0.000 title claims abstract description 62
- 239000002775 capsule Substances 0.000 title claims abstract description 47
- 238000002054 transplantation Methods 0.000 title claims abstract description 21
- 241000233866 Fungi Species 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 241000894006 Bacteria Species 0.000 claims abstract description 63
- 239000007788 liquid Substances 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 230000008569 process Effects 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 15
- 108010010803 Gelatin Proteins 0.000 claims abstract description 11
- 239000008273 gelatin Substances 0.000 claims abstract description 11
- 229920000159 gelatin Polymers 0.000 claims abstract description 11
- 235000019322 gelatine Nutrition 0.000 claims abstract description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 11
- 239000003223 protective agent Substances 0.000 claims abstract description 11
- 230000001681 protective effect Effects 0.000 claims abstract description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 10
- 229930006000 Sucrose Natural products 0.000 claims abstract description 10
- 229960004793 sucrose Drugs 0.000 claims abstract description 10
- 238000011049 filling Methods 0.000 claims abstract description 9
- 239000001963 growth medium Substances 0.000 claims abstract description 8
- 239000012153 distilled water Substances 0.000 claims abstract description 7
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 6
- 238000007710 freezing Methods 0.000 claims description 22
- 230000008014 freezing Effects 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 18
- 230000001580 bacterial effect Effects 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 238000002474 experimental method Methods 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 229930182555 Penicillin Natural products 0.000 claims description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 5
- 229940049954 penicillin Drugs 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000000859 sublimation Methods 0.000 claims description 2
- 230000008022 sublimation Effects 0.000 claims description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 229920001817 Agar Polymers 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000001888 Peptone Substances 0.000 claims 1
- 108010080698 Peptones Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 235000015278 beef Nutrition 0.000 claims 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims 1
- 235000019341 magnesium sulphate Nutrition 0.000 claims 1
- 229940099596 manganese sulfate Drugs 0.000 claims 1
- 239000011702 manganese sulphate Substances 0.000 claims 1
- 235000007079 manganese sulphate Nutrition 0.000 claims 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims 1
- 239000006872 mrs medium Substances 0.000 claims 1
- 235000019319 peptone Nutrition 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims 1
- 239000001393 triammonium citrate Substances 0.000 claims 1
- 235000011046 triammonium citrate Nutrition 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 244000234623 Coprinus comatus Species 0.000 abstract description 5
- 235000004439 Coprinus comatus Nutrition 0.000 abstract description 5
- 238000001816 cooling Methods 0.000 abstract description 4
- 239000013078 crystal Substances 0.000 abstract description 4
- 210000004211 gastric acid Anatomy 0.000 abstract description 3
- 238000010438 heat treatment Methods 0.000 description 13
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 12
- 239000000243 solution Substances 0.000 description 6
- 239000008223 sterile water Substances 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 4
- 238000010009 beating Methods 0.000 description 4
- 238000007664 blowing Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000010871 livestock manure Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229940100691 oral capsule Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000037384 Clostridium Infections Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010054236 Clostridium difficile infection Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the technical field of coprophilous fungus transplantation treatment products, and provides coprophilous fungus freeze-drying and capsule preparation processes for coprophilous fungus transplantation treatment. The preparation of the coprinus comatus capsule comprises the following processes: (1) preparing fecal bacteria liquid and reserving a sample; (2) preparing a freeze-drying protective agent; (3) preparing a culture medium; (4) freeze-drying by gradient cooling method; (5) and (5) filling into capsules. The freeze-drying protective agent comprises 10-20% of skimmed milk powder, 1-5% of cane sugar, 1-3% of gelatin and the balance of sterile distilled water. The content of the culture medium is 6.43 percent of MRS powder, and the balance is sterile distilled water. The freeze-drying protective solution can prevent water from generating ice crystals to damage bacteria in the freeze-drying process, and effectively reduces the loss of the total amount of bacteria in the freeze-drying process by matching with gradient cooling; the fecal bacteria capsule enteric capsule shell can ensure that fecal bacteria can reach the intestinal tract to play a role, and the fecal bacteria can be prevented from being killed by gastric acid.
Description
Technical Field
The invention relates to the technical field of coprophilous fungus transplantation treatment products, in particular to coprophilous fungus freeze-drying and capsule preparation processes for coprophilous fungus transplantation treatment.
Background
"Fecal transplantation" (FMT) is defined as the transplantation of functional flora in the feces of healthy people into the intestinal tract of a patient to reconstruct new intestinal flora and realize the treatment of intestinal tract and parenteral diseases.
The fecal strain transplanting technology is to utilize modern medical technology to separate fecal microbes and microbe survival maintaining matters from healthy people, transplant the microorganisms into intestinal tracts of patients and rebuild the intestinal flora of the patients so as to treat clostridium difficile infection, intractable diarrhea, constipation, gastroenteritis, Crohn's disease, ulcerative gastroenteritis and other intestinal diseases and extraintestinal diseases such as obesity, asthma, obesity, autism, depression, diabetes, cancer and other difficult and complicated diseases.
Fecal transplantation (FMT) is of concern for its superior efficacy, but fecal preparation, storage, and logistics limit its widespread use. Meanwhile, in the fecal strain transplanting process, a doctor needs to transplant fecal strains into a patient body through a nasogastric tube, a gastroscope or an enteroscope, and discomfort of the patient is easily caused.
The treatment effect of the fecal bacteria transplantation is definite, but the popularization and application need to reduce the psychological barrier of patients receiving the fecal bacteria transplantation, eliminate discomfort caused in the operation process and reduce the psychological barrier of operators implementing the fecal bacteria transplantation, and the effective technical means can be carried out only when both doctors and patients receive the method. The fecal bacteria capsule can greatly reduce the mental barrier for patients and operators at the same time. On one hand, the fecal bacteria capsule avoids uncomfortable transplanting modes such as a nasogastric tube, a gastroscope and an enteroscope which are needed by a patient, and on the other hand, the fecal bacteria capsule avoids discomfort of an implementer and exposure risk of doctors caused by spreading of diseases caused by regurgitation and cough of food of the patient in the fecal bacteria transplanting process.
A coprinus comatus capsule for coprinus comatus transplantation therapy adopts an enteric gelatin hollow capsule, and the results of experiments of disintegration outside the capsule body are good in 2 hours in an acid environment, the capsule is disintegrated within thirty minutes at pH6.8, the storage condition is simple, and the coprinus comatus capsule can be stored at-20 ℃ for one year.
At present, a plurality of methods for preparing coprinus comatus capsule freeze-drying protective agents are available on the market, such as preparing protective agents from maltodextrin, trehalose, glycerol and the like, but the methods have the following two defects in general: 1. the preservation time is short, and the preservation time of the freeze-dried fungus powder is generally about one month to half a year. 2. The invention adopts a unique freeze-drying protective agent formula, and the freeze-drying protective agent can effectively prevent ice crystals generated by water under low temperature conditions in the freeze-drying process from damaging intestinal bacteria, so that the loss of freeze-dried bacteria is reduced to about 10 percent, the problem of overlarge bacterial loss before and after freeze-drying in the world is solved, and meanwhile, the storage time of bacterial powder is prolonged to about 1 year.
Disclosure of Invention
The invention provides a fecal strain freeze-drying and capsule preparation process for fecal strain transplantation treatment, which is used for solving the problems of short preservation time after freeze-drying and overlarge loss of the total number of the fecal strains after freeze-drying, preventing ice crystals generated by water in the freeze-drying process from damaging intestinal bacteria and effectively ensuring the activity of the intestinal bacteria.
The invention relates to a preparation process of a coprophilous fungi capsule in coprophilous fungi transplantation treatment, which comprises the following steps of:
the method comprises the following steps: taking out the fecal bacteria liquid from a refrigerator at minus 80 ℃, unfreezing the fecal bacteria liquid in a water bath kettle at 37 ℃ for 20-30min, taking out the fecal bacteria liquid, putting the fecal bacteria liquid into a centrifugal machine, and centrifuging the fecal bacteria liquid at 5000r and 4 ℃ for 5 min.
Step two: and (5) preparing a freeze-drying protective agent.
Step three: preparing a culture medium: dissolving 12.9g of MRS culture medium in 200ml of conical flask filled with distilled water, mixing uniformly while stirring, adjusting pH to 7.3 +/-0.2, and sterilizing at 121 ℃ for 20min in an autoclave.
Step four: and taking out the centrifuged bacterial liquid, adding 10ml of freeze-drying protective agent into each tube, and uniformly mixing by using a mixing instrument.
Step five: and (4) sample retention: taking five freezing storage tubes with the serial numbers of 1, 2, 3, 4 and 5, adding 0.5ml of uniformly mixed bacteria liquid into each tube, and respectively performing sample retention experiments on the first day, the first week, the first month, the third month and the first year.
Step six: subpackaging: adding each tube of bacterial liquid into the west forest, wherein the liquid level is about 1cm, simultaneously placing penicillin bottles and five freezing tubes for reserving samples into a freeze dryer, setting the pre-freezing temperature to be-45 ℃, freeze-drying for 48 hours, and controlling the humidity below 40 after freeze-drying.
Step seven: filling: pouring the freeze-dried powder onto a capsule filling plate, and filling a No. 0 capsule. And (4) storing the filled capsules and the preserved freezing tubes in a refrigerator at the temperature of-20 ℃.
The preparation method of the fecal bacteria liquid in the first step comprises the following steps:
s1, uniformly stirring and diluting the excrement:
adding 50g of in vitro fresh excrement into 800ml of 0.9% sterile normal saline with the temperature of 2-6 ℃, manually stirring for 1-2 minutes by using a glass plate, and fully and uniformly stirring for about five minutes by using a magnetic stirrer (the rotating speed of the stirrer is 500 r/min).
S2, filtering:
filtering with stainless steel filter screen on the ultra-clean workbench, sequentially filtering according to 60 mesh and 80 mesh, removing feces residue and large particulate matter, and collecting the final filtrate to obtain the whole feces bacterium solution.
S3, centrifugation:
and (3) subpackaging 45ml of fecal strain liquid into centrifuge tubes, weighing to ensure that the weight deviation of each bottle of fecal strain liquid is not more than 0.5, and symmetrically placing the bottles into a centrifuge after the weighing is finished.
First centrifugation: rotating at a speed of 5000r/min and at a temperature of 10-15 ℃ for 1min, removing supernatant and leaving precipitate;
secondly, resuspending for the first time: adding 0.9% sterile physiological saline at 4 deg.C into the precipitate to 45ml, and shaking with oscillator to obtain resuspension;
third centrifugation: rotating at speed of 5000r/min and temperature of 10 deg.C for 1min, removing supernatant, and collecting precipitate;
fourthly, resuspending for the second time: adding physiological saline with the temperature of 4 ℃, adding 45ML of saline into each tube, and uniformly mixing by using an oscillator;
filtering: filtering the second re-suspended liquid manure with a 80-mesh filter screen;
sixthly, adding 5ML of glycerol with the concentration of 10 percent, and uniformly mixing to obtain a full-fecal bacteria liquid;
and seventhly, preservation: and (3) sticking a freezing label to each tube of the whole manure liquid with the volume of about 45ML, cooling for 1 hour in a refrigerator at the temperature of-4 ℃, and then storing in a refrigerator at the temperature of-70-90 ℃ for 10-15 months.
The freeze-drying protective solution related in the step two mainly comprises skimmed milk powder, cane sugar, glycerol and sterile water, and the freeze-drying protective solution comprises the following components in percentage by weight: 10-20% of skimmed milk powder, 1-5% of sucrose, 1-3% of gelatin and 72-88% of sterile water.
Further, the sucrose is pure sucrose, and the gelatin is 180 freezing strength gelatin.
The preparation and preservation method of the freeze-drying protective solution comprises the following steps:
weighing 18g of skimmed milk powder, 1g of sucrose and 3g of gelatin by using weighing paper, pouring into a conical flask, adding 60 ℃ distilled water, adding water and uniformly mixing until the volume is 100 ml;
② putting the evenly mixed freeze-drying protective solution into a high-temperature high-pressure sterilization pot, and sterilizing for 20min at 121 ℃.
The freeze-drying process of the fecal strain liquid involved in the step six comprises the following steps:
putting the prepared fecal strain liquid into a refrigerator at the temperature of minus 4 ℃ for 30min, taking out, and putting into a refrigerator at the temperature of minus 20 ℃ for 60 min.
Secondly, taking the fecal bacteria liquid out of a refrigerator at the temperature of 20 ℃ below zero, and putting the fecal bacteria liquid into a freeze dryer.
Setting freeze-drying parameters, and freeze-drying through several steps of pre-freezing, vacuumizing and subliming:
s1, pre-freezing: the temperature is-35 ℃ to-45 ℃, and the pre-freezing time is 150-180 min;
s2, vacuumizing: the vacuum degree is 0.2, and the vacuumizing time is 20-30 min;
s3, sublimation: dividing into 9 gradients, increasing the temperature of each gradient by 5 ℃, increasing the temperature from-35 ℃ to 30 ℃, increasing the temperature between each gradient for 10min, and keeping the temperature of each temperature node constant for 30-120 min;
s4, sterilization: sterilizing with ultraviolet lamp for 40-60 min;
and fourthly, taking out the sample, opening an air inlet valve after freeze-drying is finished, filling high-purity nitrogen, sealing the freeze-dried powder, and filling the freeze-dried powder in the next step.
Further, high-purity nitrogen is introduced for protection in the whole freeze-drying process.
The invention has the beneficial effects that:
(1) the freeze-drying protective solution can avoid the damage of bacteria caused by water ice crystals in the freeze-drying process, and the loss of the total amount of bacteria in the freeze-drying process is effectively reduced by matching with gradient cooling;
(2) the coprophilous fungi are freeze-dried and then prepared into an oral capsule, the effect of the oral capsule is not inferior to that of a colonoscope transplantation mode, the psychological barrier of patients receiving coprophilous fungi transplantation is reduced, and the uncomfortable physiological reaction in the treatment process is eliminated;
(3) the fecal bacteria capsule enteric capsule shell can ensure that fecal bacteria can reach the intestinal tract to play a role, and the fecal bacteria can be prevented from being killed by gastric acid.
Drawings
FIG. 1: diluting 1ml of fecal strain liquid by 103 times before freeze-drying, and taking 200 mul of lactobacillus for growth;
FIG. 2: after the lm fecal strain liquid is freeze-dried and diluted to the same times, taking 200 mul of lactobacillus for growth;
FIG. 3: before freeze-drying, 1ml of fecal strain liquid is diluted to 106 times, and 200 mul of whole strain growth condition is taken;
FIG. 4: freeze-drying 1ml of fecal strain liquid, diluting to the same multiple, and taking 200 mul of whole-strain growth condition;
FIG. 5: developing the fecal bacteria capsule under X-ray;
FIG. 6: images of fecal bacteria capsule under capsule gastroscope.
Detailed Description
In order to make the technical scheme and advantages of the embodiment of the invention clearer, the technical scheme is more clearly and thoroughly understood by combining two comparison experiments which are carried out before.
Example 1
And (3) taking a part of excrement of the volunteer according with the requirements of the donor, preparing 6 tubes of excrement liquid, centrifuging, removing supernatant, and adding 10ml of freeze-drying protective agent into each tube. And (3) uniformly mixing by using a mixing instrument, and subpackaging penicillin bottles, wherein the liquid level of each penicillin bottle is about 1 cm. Meanwhile, 0.5ml of sample is kept in a freezing tube and put into a Christ Epsilon 2-6D LSC plus freeze dryer together for freeze drying.
The freeze-drying parameters are as follows:
pre-freezing at-45 deg.C for 180 min;
vacuumizing, wherein the vacuum degree is 0.2, and the vacuumizing time is 20 min;
sublimating at-35 deg.C for 10min for 120 min; heating to-30 deg.C for 10min for 60 min; heating to-25 deg.C for 10min for 60 min; heating at-20 deg.C for 10min for 60 min; heating to-15 deg.C for 10min for 60 min; heating to-10 deg.C for 10min, and maintaining for 180 min; heating at-5 deg.C for 10min for 60 min; heating to-0 deg.C for 10min for 60 min; heating at 5 deg.C for 10min for 60 min; heating at 10 deg.C for 10min for 120 min; heating at 15 deg.C for 10min for 60 min; heating at 20 deg.C for 10min for 30 min; heating at 25 deg.C for 10min for 30 min; heating at 30 deg.C for 10min, and maintaining for 30 min.
Charging high-purity nitrogen to remove vacuum, taking out sample, rapidly encapsulating, and storing in-80 deg.C refrigerator.
Taking out the capsule the next day, adding 0.12g of the capsule into a freezing storage tube, and performing a culture experiment of indicator bacteria lactic acid bacteria and total number of bacteria.
The specific operation steps of the indicator bacterium culture are as follows:
seven test tubes are respectively numbered as 1, 2, 3, 4, 5, 6, 7 and 8, and 9ml of sterile water is added into each test tube;
adding sterile water into the freezing tube, uniformly mixing to 1ml, completely taking out the mixture by using a pipette, adding the mixture into a No. 1 test tube, blowing, beating and uniformly mixing; taking 1ml from the test tube 1, adding into the test tube No. 2, and blowing, beating and uniformly mixing; repeating the steps until the number 8 test tubes are reached, wherein the dilution times of the bacterial liquid in the number 1-8 test tubes are respectively 10-1、10-2、10-3、10-4、10-5、10-6、10-7、10-8；
③ coating the plates, respectively taking 10-3、10-4、10-5Dripping 200 mul of the three-gradient diluent into an MRS culture medium, and uniformly coating by using a coating rod;
fourthly, putting the coated flat plate into an anaerobic incubator for culture at 37 ℃;
taking out the flat plate after 48h, taking a picture, and counting.
The specific operation steps of total bacteria culture are as follows:
seven test tubes are respectively numbered as 1, 2, 3, 4, 5, 6, 7 and 8, and 9ml of sterile water is added into each test tube;
adding sterile water into the freezing tube, uniformly mixing to 1ml, completely taking out the mixture by using a pipette, adding the mixture into a No. 1 test tube, blowing, beating and uniformly mixing; taking 1ml from the test tube 1, adding into the test tube No. 2, and blowing, beating and uniformly mixing; repeating the steps until the number 8 test tubes are reached, wherein the dilution times of the bacterial liquid in the number 1-8 test tubes are respectively 10-1、10-2、10-3、10-4、10-5、10-6、10-7、10-8；
③ coating the plates, respectively taking 10-6、10-7、10-8200 μ l of the three-gradient dilutions were added dropwise to the TSA medium and spread evenly with a spreading bar;
fourthly, putting the coated flat plate into an anaerobic incubator for culture at 37 ℃;
taking out the flat plate after 48h, taking a picture, and counting.
The average value of the total number cfu of the lactic acid bacteria after freeze-drying is 3.19 multiplied by 107Mean difference of 9X 105The survival rate of lactobacillus before and after freeze-drying is 95.2 percent. Example 1 the total number of whole bacteria cfu was 8.65X 10 as a result of whole bacteria culture before lyophilization11The average value of the total number cfu of the whole bacteria after freeze-drying is 8.23 multiplied by 1011The average value of viable count N is 11.94, and the survival rate of the whole bacteria before and after freeze-drying is 95.1%.
Example 1 indicators bacteria results of bacterial counts from three parallel experiments, see table below:
the bacterial loss rate before and after freeze-drying is less than 5 percent as can be seen from the index bacterial culture and whole bacterial culture results in example 1.
Clinical trial
The disintegration process of the fecal bacteria capsule in vivo is verified by two methods.
Barium sulfate is filled into a capsule shell for manufacturing the fecal bacteria capsule, two testers take the barium sulfate respectively, one testers takes the barium sulfate and develops the barium sulfate by taking an X-ray film, as shown in figure 5, the barium sulfate enters the small intestine after the capsule stays in the stomach for 24 minutes, and the barium sulfate runs in the small intestine for 4 hours and 05 minutes. Another example was observed under a capsule endoscope, and as shown in FIG. 6, 30ml of drinking water was fed into the barium capsule, left in the stomach for about 20 minutes, and completely dissolved after running in the small intestine for 1 hour and 56 minutes (jejunal segment).
Clinical tests show that the enteric capsule shell of the fecal bacteria capsule can ensure that fecal bacteria can reach the intestinal tract to play a role, and the fecal bacteria can be prevented from being killed by gastric acid.
While the foregoing embodiments are illustrative of the present invention, various modifications and changes may be readily made by those skilled in the art based upon the teachings and principles of this invention, which are intended to be limited not to the details of construction and methods herein shown, but rather to the preferred embodiments described, and therefore all equivalent modifications and changes in light of the above teachings are intended to be included within the scope of the present invention as defined in the appended claims.
Claims (8)
1. A coprophilous fungus freeze-drying and capsule preparation process for coprophilous fungus transplantation treatment is characterized in that the coprophilous fungus freeze-drying comprises the following steps:
the method comprises the following steps: preparing a fecal strain liquid: uniformly stirring and diluting fresh excrement and 0.9% sterile normal saline at the temperature of 2-6 ℃, filtering by a multi-stage filter screen, taking final filtrate to obtain a whole excrement liquid, centrifuging and resuspending the obtained whole excrement liquid for multiple times, centrifuging to remove supernatant, leaving precipitate, shaking the precipitate by a vibrator to obtain a heavy suspension, and finally uniformly mixing the heavy suspension and glycerol and storing in a refrigerator at the temperature of-70-90 ℃ for 10-15 months;
step two: preparing a freeze-drying protective solution: the freeze-drying protective solution comprises the following components in percentage by weight: 10 to 20 percent of skimmed milk powder, 1 to 5 percent of cane sugar, 1 to 3 percent of gelatin and the balance of sterile distilled water;
step three: freeze-drying by using a freeze-dryer, wherein the freeze-drying process and freeze-drying parameters are as follows:
s1, pre-freezing: the temperature is-35 ℃ to-45 ℃, and the pre-freezing time is 150-180 min;
s2, vacuumizing: the vacuum degree is 0.2, and the vacuumizing time is 20-30 min;
s3, sublimation: dividing into 9 gradients, increasing the temperature of each gradient by 5 ℃, increasing the temperature from-35 ℃ to 30 ℃, increasing the temperature between each gradient for 10min, and keeping the temperature of each temperature node constant for 30-120 min;
s4, sterilization: sterilizing with an ultraviolet lamp for 40-60 min.
2. The process of claim 1, wherein the sucrose is pure sucrose and the gelatin is 180 freezing strength gelatin.
3. The process of claim 1, wherein the freeze-drying process of step three is protected by introducing high-purity nitrogen throughout the freeze-drying process.
4. The method for preparing the freeze-drying protective solution for the freeze-drying of coprophila according to claim 1, wherein the method for preparing the freeze-drying protective solution comprises the following steps:
(1) weighing 18g of skimmed milk powder, 1g of sucrose and 3g of gelatin by using weighing paper, pouring into a conical flask, adding 60 ℃ distilled water, adding water and uniformly mixing to 100 ml;
(2) placing the uniformly mixed freeze-dried protective solution into a high-temperature high-pressure sterilization pot, and sterilizing for 20min at 121 ℃.
5. A preparation process of a coprophila fungus capsule for coprophila fungus transplantation treatment is characterized in that the process of the capsule preparation process comprises the following steps:
the method comprises the following steps: taking out the fecal bacteria liquid from a refrigerator at minus 80 ℃, unfreezing the fecal bacteria liquid in a water bath kettle at 37 ℃ for 20-30min, taking out the fecal bacteria liquid, putting the fecal bacteria liquid into a centrifugal machine, and centrifuging the fecal bacteria liquid at 5000r and 4 ℃ for 5 min;
step two: preparing a freeze-drying protective agent;
step three: preparing a culture medium;
step four: taking out the centrifuged bacterial liquid, adding 10ml of freeze-drying protective agent into each tube, uniformly mixing by using an oscillator, respectively reserving 1ml of sample by using two freezing tubes, and performing a bacterial counting experiment before freeze-drying by using one tube;
step five: and (4) sample retention: taking five freezing storage tubes with the serial numbers of 1, 2, 3, 4 and 5, adding 1ml of uniformly mixed bacteria liquid into each tube, and respectively performing a sample-reserving bacteria counting experiment on the first day, the first week, the first month, the third month and the first year;
step six: subpackaging: adding each tube of bacterial liquid into a penicillin bottle, simultaneously placing the penicillin bottle and five freezing tubes for sample preservation into a freeze dryer, setting the pre-freezing temperature to be-45 ℃, freeze-drying for 24 hours, and controlling the humidity below 40 after freeze-drying;
step seven: filling: pouring the freeze-dried powder onto a capsule filling plate, and filling a No. 0 capsule;
and (4) storing the filled capsules and the preserved freezing tubes in a refrigerator at the temperature of-20 ℃.
6. The process for preparing a fecal bacteria capsule for fecal bacteria transplantation therapy according to claim 5, wherein the formula components (g/L) of the culture medium are: 10g of peptone, 5g of beef powder, 4g of yeast powder, 20g of glucose, 801 ml of tween, 2g of dipotassium hydrogen phosphate, 5g of sodium acetate, 2g of triammonium citrate, 0.2g of magnesium sulfate, 0.05g of manganese sulfate and 15g of agar.
7. The process for preparing a fecal bacteria capsule for fecal bacteria transplantation therapy according to claim 5, wherein the preparation method of the culture medium comprises: dissolving 12.9g of MRS medium in 200ml of conical flask filled with distilled water, mixing uniformly while stirring, adjusting pH to 7.3 + -0.2, and sterilizing at 121 deg.C for 20min in autoclave.
8. The process of claim 5, wherein the fecal bacteria capsule is selected from enteric gelatin hollow capsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110070100.1A CN112656766A (en) | 2021-01-19 | 2021-01-19 | Fecal fungus freeze-drying and capsule preparation process for fecal fungus transplantation treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110070100.1A CN112656766A (en) | 2021-01-19 | 2021-01-19 | Fecal fungus freeze-drying and capsule preparation process for fecal fungus transplantation treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112656766A true CN112656766A (en) | 2021-04-16 |
Family
ID=75415733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110070100.1A Pending CN112656766A (en) | 2021-01-19 | 2021-01-19 | Fecal fungus freeze-drying and capsule preparation process for fecal fungus transplantation treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112656766A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922158A (en) * | 2015-06-05 | 2015-09-23 | 中国人民解放军第三军医大学第三附属医院 | Fecal microbiota capsule, as well as preparation method and application thereof |
| CN107574134A (en) * | 2017-10-20 | 2018-01-12 | 南京益恒寿生命科技有限公司 | A kind of caprophyl transplantation treatment Plays caprophyl lyophiled powder preparing technique |
| CN109679877A (en) * | 2019-01-17 | 2019-04-26 | 广州承葛生物科技有限公司 | A kind of preparation method of high activity caprophyl capsule |
-
2021
- 2021-01-19 CN CN202110070100.1A patent/CN112656766A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922158A (en) * | 2015-06-05 | 2015-09-23 | 中国人民解放军第三军医大学第三附属医院 | Fecal microbiota capsule, as well as preparation method and application thereof |
| CN107574134A (en) * | 2017-10-20 | 2018-01-12 | 南京益恒寿生命科技有限公司 | A kind of caprophyl transplantation treatment Plays caprophyl lyophiled powder preparing technique |
| CN109679877A (en) * | 2019-01-17 | 2019-04-26 | 广州承葛生物科技有限公司 | A kind of preparation method of high activity caprophyl capsule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11504403B2 (en) | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | |
| JP6907288B2 (en) | Microbiota Recovery Therapy (MRT) Composition | |
| CN104922158B (en) | Caprophyl capsule and its preparation and application | |
| CN112080445A (en) | Lactobacillus plantarum ZJ316 and application thereof in inhibiting helicobacter pylori | |
| JP2018514228A (en) | Method for preparing a stool microbial sample | |
| CN109609420B (en) | Helicobacter pylori-resistant probiotic composition and preparation method thereof | |
| CN112273658A (en) | Preparation method of bifidobacterium microcapsules based on endogenous emulsification | |
| CN113133505A (en) | Preparation method of micro-ecological compound preparation containing clostridium butyricum | |
| WO2019241523A1 (en) | Microbiota restoration therapy (mrt) compositions and methods of manufacture | |
| CN116574648A (en) | Lactobacillus plantarum and application thereof in relieving constipation | |
| CN112336753A (en) | Intestinal flora capsule and preparation method and application thereof | |
| CN112656766A (en) | Fecal fungus freeze-drying and capsule preparation process for fecal fungus transplantation treatment | |
| CN116392511A (en) | Preparation method and application of lactobacillus rhamnosus outer membrane vesicle and outer membrane vesicle product | |
| CN116570029A (en) | Walnut oligopeptide probiotics microcapsule and preparation method thereof | |
| CN107034159B (en) | Pathogenic bacteria antagonist and application thereof | |
| CN110938563B (en) | Lactobacillus BJ-REBORN001 and application thereof in preparation of helicobacter pylori inhibiting fermentation broth | |
| CN114404384A (en) | Oral capsule for intestinal flora transplantation and preparation method thereof | |
| CN111888381A (en) | Intestinal microorganism transplanting process | |
| CN116103197B (en) | Streptococcus thermophilus with helicobacter pylori inhibiting effect and application thereof | |
| CN114042090A (en) | Intestinal flora capsule and preparation method thereof | |
| CN116370508A (en) | Fecal fungus transplanting liquid for improving growth performance of development retardation piglets and preparation and application thereof | |
| CN114129599A (en) | Application of silkworm chrysalis in preparation of product for directionally promoting proliferation of intestinal probiotics | |
| CN117025479A (en) | Lactobacillus formatus SHMB0001 and application thereof in preventing and relieving acute colitis | |
| CN115895899A (en) | Freeze-drying protective agent and freeze-drying process of fecal fungi | |
| US20180133323A1 (en) | Optimized Fecal Microbiota Transplantation Carrier Medium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210416 |
|
| RJ01 | Rejection of invention patent application after publication |